OncoMatch

OncoMatch/Clinical Trials/NCT05450029

Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer

Is NCT05450029 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sintilimab for rectal cancer.

Phase 2RecruitingYanhong DengNCT05450029Data as of May 2026

Treatment: SintilimabImmunoscore has been reported to be superior to microsatellite instability staging in predicting the disease-specific recurrence and survival for patients with colorectal cancer. However, the relationship between Immunoscore and its impact on patient's response to PD-1 blockade remains to be elucidated. This phase II, prospective, open label study is designed to evaluate the efficacy and safety of combination neoadjuvant chemoradiotherapy (nCRT) with the anti-PD-1 antibody sintilimab for intermediate/high Immunoscore locally advanced rectal cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Disease stage

Required: Stage N POSITIVE

Clinical stage of T3/T4 or N positive and M0, before nCRT

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: anti-PD-1/PD-L1/PD-L2 therapy

history of anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy

Cannot have received: investigational drug

Current or recent (within 4 weeks prior to starting study treatment) treatment of another investigational drug or participation in another investigational study

Lab requirements

Blood counts

leukocytes ≥ 3,000/k/ul; absolute neutrophil count ≥ 1,500/k/ul; platelet count ≥ 100,000/k/ul

Kidney function

serum creatinine ≤ 1.5 x institute upper limit of normal (uln)

Liver function

total bilirubin ≤ 1.5 x institutional upper limit of normal (uln); ast (sgot) ≤ 2.5 x institutional upper limit of normal (uln); alt (sgpt) ≤ 2.5 x institutional upper limit of normal (uln)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify